Antonios K. Bertsias

Irakleion, ESYE43, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.

Journal: Arthritis research & therapy

Published: October 08, 2025

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Journal: Seminars in arthritis and rheumatism

Published: October 02, 2025

Clinical Impact of FDG PET/CT in Pulmonary Nodule Characterization: Current Perspectives on Dual-Time-Point Imaging and Semi-Quantitative Imaging Metrics.

Clinical Impact of FDG PET/CT in Pulmonary Nodule Characterization: Current Perspectives on Dual-Time-Point Imaging and Semi-Quantitative Imaging Metrics.

Journal: Cancers

Published: September 09, 2025

Difficult-to-Manage Axial Spondyloarthritis.

Difficult-to-Manage Axial Spondyloarthritis.

Journal: Mediterranean journal of rheumatology

Published: November 13, 2024

Latest vaccination trends against herpes zoster within two primary care settings in Crete, Greece: Rates and perception driven determinants.

Latest vaccination trends against herpes zoster within two primary care settings in Crete, Greece: Rates and perception driven determinants.

Journal: Semergen

Published: June 18, 2024

A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.

A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.

Journal: Cells

Published: October 25, 2023

Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.

Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.

Journal: RMD open

Published: October 14, 2023

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.

Journal: Rheumatology international

Published: June 27, 2023

Clinical and Social Features of Patients with Eye Injuries Admitted to a Tertiary Hospital: A Five-Year Retrospective Study from Crete, Greece.

Clinical and Social Features of Patients with Eye Injuries Admitted to a Tertiary Hospital: A Five-Year Retrospective Study from Crete, Greece.

Journal: Healthcare (Basel, Switzerland)

Published: January 13, 2023

Ocular trauma, visual acuity related to time of referral and psychosocial determinants, during COVID‑19 pandemic: A prospective study.

Ocular trauma, visual acuity related to time of referral and psychosocial determinants, during COVID‑19 pandemic: A prospective study.

Journal: Experimental and therapeutic medicine

Published: November 29, 2022

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.

Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.

Journal: Frontiers in immunology

Published: October 19, 2022

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.

Journal: Arthritis research & therapy

Published: August 20, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026